Actively Recruiting
Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction
Led by Beijing Luhe Hospital · Updated on 2024-05-22
84
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute ST-segment elevation myocardial infarction (STEMI) is a common manifestation of cardiovascular emergencies. Percutaneous coronary intervention (PCI) and guideline-recommended pharmacotherapy have reduced mortality rates associated with STEMI, but the incidence of recurrent ischemic events, particularly early ischemic events, remains high. Current research suggests that low-density lipoprotein cholesterol (LDL-C) levels not meeting guideline-recommended levels and inflammation are closely related to early recurrent ischemic events. Evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, rapidly and effectively reduces LDL-C levels and suppresses inflammation. Long-term use in patients with acute coronary syndromes can reverse atherosclerosis and improve prognosis. However, data on its use in STEMI patients are limited, particularly regarding the cardioprotective effects of preoperative administration of 420mg evolocumab subcutaneous injection. This study aims to evaluate the effects of administering evolocumab 420mg before emergency PCI on lipid profiles, inflammatory markers, myocardial injury, and short-term prognosis in STEMI patients through a single-center, randomized, open-label study. It aims to provide theoretical evidence for further reducing the risk of recurrent cardiovascular events in STEMI and identifying more optimized treatment strategies.
CONDITIONS
Official Title
Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients treated at Beijing Luhe Hospital with direct PCI for STEMI
- Chest pain lasting at least 30 minutes with ST-segment elevation ≥ 0.1 mV in two adjacent leads on ECG
- Symptoms started within the past 24 hours
- Age between 18 and 80 years
- Signed informed consent form
You will not qualify if you...
- Hemodynamically unstable or Killip grade 2 or higher
- Severe kidney failure with glomerular filtration rate below 30 ml/min/1.73m²
- Active liver disease or liver dysfunction with AST or ALT more than three times the upper limit
- Allergy to any study medication
- Previous or planned use of PCSK9 inhibitors
- Suspected stress cardiomyopathy or acute pericarditis
- Malignant tumors requiring treatment or other serious systemic diseases
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing luhe hospital
Beijing, China
Actively Recruiting
Research Team
R
rui yan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here